CNSP

3.5609.07%
EF

Eric Faulkner

Chief Technology Officer

Mr. Eric Faulkner, M.Sc., M.B.A., is Chief Technology Officer of CNS Pharmaceuticals, Inc. from March 2, 2026. He serves as Chief Technical Officer at IO Biotech ApS Since July 2023. He was Senior Vice President of CMC of IO Biotech ApS from 2022 until July 2023. He was Senior Vice President of CMC of IO Biotech, Inc. from November 2022 until July 2023 and served as its Chief Technical Officer since July 2023 until March 31, 2026. Mr. Faulkner has technical operations, quality and product launch experience within the biotechnology industry. Mr. Faulkner has experience in product development, manufacturing operations, supply chain and commercialization of peptides, proteins, monoclonal antibodies, viruses and combination products. Prior to joining IO Biotech, Mr. Faulkner held senior roles at Homology Medicines as head of CMC management and external manufacturing, product operations lead for the Rare Disease Business Unit at Shire (Takeda) and spent over 15 years at Biogen involved in the development and commercialization of Avonex®, Tysabri® and Tecfidera®. Mr. Faulkner obtained his Master of Science degree in biotechnology and biomedical science at the University of Massachusetts and has a Master of Business Administration from Boston University and a B.S. in Biology from SUNY Fredonia.

Positions